You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

XML
Research Article
Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: December 2019 to September 2025

AbstractFullPdf
Dec 2019330
Jan 202012120
Feb 202032323
Mar 202031313
Apr 202035353
May 202034342
Jun 202022220
Jul 202025251
Aug 202012123
Sep 202024242
Oct 202038384
Nov 202018183
Dec 202011112
Jan 202120202
Feb 202125256
Mar 202153534
Apr 202146468
May 202145453
Jun 202163634
Jul 202155553
Aug 202136360
Sep 202145458
Oct 2021212112
Nov 2021373711
Dec 202140405
Jan 2022686913
Feb 202242448
Mar 2022596512
Apr 202265667
May 2022485010
Jun 202264643
Jul 202277799
Aug 2022979811
Sep 20221291332
Oct 202212612812
Nov 2022596115
Dec 202252529
Jan 202377788
Feb 2023991016
Mar 202310810911
Apr 202379816
May 2023949514
Jun 202374766
Jul 2023878812
Aug 2023818310
Sep 202369716
Oct 202313813815
Nov 2023899211
Dec 202354555
Jan 2024333412
Feb 2024575810
Mar 202410310611
Apr 202479807
May 202464647
Jun 202470706
Jul 202479809
Aug 202434377
Sep 2024393913
Oct 202448498
Nov 2024444814
Dec 202451526
Jan 2025383811
Feb 202550509
Mar 202532329
Apr 2025848410
May 2025323212
Jun 202527276
Sep 2025110
Total36833740480